Analysts Expect a 10% Increase for IYY
ETF Analysis: The iShares Dow Jones U.S. ETF (IYY) has an implied analyst target price of $178.58, indicating a potential upside of 9.53% from its current trading price of $163.04.
Notable Holdings: Key underlying holdings with significant upside potential include First Horizon Corp (10.63% upside), Exelixis Inc (10.12% upside), and Evercore Inc (10.06% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with current market conditions.
Further Research Needed: Investors are encouraged to conduct additional research to assess the validity of the analysts' targets in light of recent developments in the companies and their industries.
Trade with 70% Backtested Accuracy
Analyst Views on EXEL
About EXEL
About the author
Exelixis Posts Strong Earnings—Could New Highs Be on the Horizon?
Earnings Report Overview: Exelixis, Inc. reported earnings per share of 94 cents, exceeding consensus estimates by 27%, but its revenue of $598.66 million fell short of expectations, leading to a 2% decline in stock price.
Future Growth Strategy: The company is focusing on expanding its franchise strategy and investing in research and development, particularly around its drug candidate, zanidatamab, which targets colorectal cancer.
Market Positioning: Exelixis is transitioning from a single-product company to a multi-franchise player in oncology, with forecasts suggesting potential peak annual sales of $5 billion if zanidatamab receives regulatory approval.
Investment Outlook: Analysts maintain an equal weight rating on Exelixis stock, with price targets being raised, indicating confidence in the company's growth potential despite current stock consolidation patterns.
Exelixis Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Exelixis reported total revenues of approximately $599 million for Q4 2025, with cabozantinib product revenues at $546.6 million, demonstrating sustained growth in the oncology sector and reinforcing its market leadership.
- Product Line Expansion: CEO Michael Morrissey highlighted that cabozantinib's U.S. net revenues exceeded $100 million for neuroendocrine tumors in 2025, indicating the strategic success of the company's diversified oncology treatment portfolio.
- Optimistic Future Outlook: CFO Christopher Senner reiterated the 2026 financial guidance, estimating gross to net margins between 31% and 32%, reflecting confidence in future growth while planning to continue share repurchases to enhance shareholder value.
- Market Dynamics Monitoring: Management expressed concerns about variability in 340B purchasing behavior, anticipating continued fluctuations in 2026 that could impact net revenues, highlighting the complexities and uncertainties of market competition.
EXELIXIS Q4 ADJUSTED EPS REACHES USD 0.94, BEATING IBES ESTIMATE OF USD 0.79
Earnings Report: EXELIXIS reported a Q4 adjusted EPS of $0.94, indicating strong financial performance.
Comparison with Estimates: The reported EPS surpassed the IBES estimate of $0.79, reflecting better-than-expected results.
Exelixis Q4 Earnings Beat Expectations with Strong Guidance
- Earnings Beat: Exelixis reported a Q4 non-GAAP EPS of $0.97, exceeding expectations by $0.16, which reflects improved profitability and may bolster investor confidence moving forward.
- Revenue Miss: The total revenue of $598.66 million, while up 5.6% year-over-year, fell short of the consensus estimate by $2.44 million, indicating potential pressures from increased market competition affecting sales.
- 2026 Guidance Maintained: Exelixis is maintaining its financial guidance for fiscal year 2026, projecting total revenues between $2.525 billion and $2.625 billion, which demonstrates confidence in future growth despite market expectations of $2.60 billion.
- R&D Investment Plans: The company plans to allocate $875 million to $925 million for research and development, underscoring its ongoing commitment to innovative drug development, which could lay the groundwork for future product line expansions.
Exelixis Set to Announce Q4 Earnings on February 10th
- Earnings Announcement: Exelixis (EXEL) is set to announce its Q4 earnings on February 10th after market close, with consensus EPS estimated at $0.81, reflecting a significant 47.3% year-over-year growth, indicating the company's robust performance in the oncology sector.
- Revenue Expectations: The revenue estimate for Q4 stands at $601.1 million, representing a 6.1% year-over-year increase; however, the revenue forecast has faced eight downward revisions in the last three months, suggesting some market volatility.
- Performance Track Record: Over the past two years, Exelixis has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong operational capabilities and potentially attracting more investor interest ahead of the earnings report.
- Analyst Rating Changes: Despite BofA downgrading Exelixis to Underperform due to valuation concerns and a lack of catalysts, the anticipation surrounding a potential FDA approval could still drive the stock price higher, reflecting a nuanced market perspective on the company's future prospects.
Exelixis' NDA for Zanzalintinib Accepted by FDA for Review
- FDA Review Progress: Exelixis announced that its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer has been accepted for review by the FDA, with a target action date of December 3, 2026, marking a significant advancement in cancer treatment.
- Clinical Trial Results: The phase 3 STELLAR-303 trial demonstrated that the combination of zanzalintinib and atezolizumab significantly improved median overall survival and reduced the risk of death, highlighting its potential in treating metastatic colorectal cancer.
- Market Demand Response: The introduction of zanzalintinib addresses the urgent need for effective therapies for previously treated metastatic colorectal cancer patients, potentially enhancing Exelixis' competitive position in the oncology market.
- Future Outlook: Exelixis plans to collaborate closely with the FDA to expedite the review process for zanzalintinib, which, if approved, could provide new hope for patients with metastatic colorectal cancer and further solidify the company's leadership in innovative drug development.
Exelixis Posts Strong Earnings—Could New Highs Be on the Horizon?
Earnings Report Overview: Exelixis, Inc. reported earnings per share of 94 cents, exceeding consensus estimates by 27%, but its revenue of $598.66 million fell short of expectations, leading to a 2% decline in stock price.
Future Growth Strategy: The company is focusing on expanding its franchise strategy and investing in research and development, particularly around its drug candidate, zanidatamab, which targets colorectal cancer.
Market Positioning: Exelixis is transitioning from a single-product company to a multi-franchise player in oncology, with forecasts suggesting potential peak annual sales of $5 billion if zanidatamab receives regulatory approval.
Investment Outlook: Analysts maintain an equal weight rating on Exelixis stock, with price targets being raised, indicating confidence in the company's growth potential despite current stock consolidation patterns.
Exelixis Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Exelixis reported total revenues of approximately $599 million for Q4 2025, with cabozantinib product revenues at $546.6 million, demonstrating sustained growth in the oncology sector and reinforcing its market leadership.
- Product Line Expansion: CEO Michael Morrissey highlighted that cabozantinib's U.S. net revenues exceeded $100 million for neuroendocrine tumors in 2025, indicating the strategic success of the company's diversified oncology treatment portfolio.
- Optimistic Future Outlook: CFO Christopher Senner reiterated the 2026 financial guidance, estimating gross to net margins between 31% and 32%, reflecting confidence in future growth while planning to continue share repurchases to enhance shareholder value.
- Market Dynamics Monitoring: Management expressed concerns about variability in 340B purchasing behavior, anticipating continued fluctuations in 2026 that could impact net revenues, highlighting the complexities and uncertainties of market competition.
EXELIXIS Q4 ADJUSTED EPS REACHES USD 0.94, BEATING IBES ESTIMATE OF USD 0.79
Earnings Report: EXELIXIS reported a Q4 adjusted EPS of $0.94, indicating strong financial performance.
Comparison with Estimates: The reported EPS surpassed the IBES estimate of $0.79, reflecting better-than-expected results.
Exelixis Q4 Earnings Beat Expectations with Strong Guidance
- Earnings Beat: Exelixis reported a Q4 non-GAAP EPS of $0.97, exceeding expectations by $0.16, which reflects improved profitability and may bolster investor confidence moving forward.
- Revenue Miss: The total revenue of $598.66 million, while up 5.6% year-over-year, fell short of the consensus estimate by $2.44 million, indicating potential pressures from increased market competition affecting sales.
- 2026 Guidance Maintained: Exelixis is maintaining its financial guidance for fiscal year 2026, projecting total revenues between $2.525 billion and $2.625 billion, which demonstrates confidence in future growth despite market expectations of $2.60 billion.
- R&D Investment Plans: The company plans to allocate $875 million to $925 million for research and development, underscoring its ongoing commitment to innovative drug development, which could lay the groundwork for future product line expansions.
Exelixis Set to Announce Q4 Earnings on February 10th
- Earnings Announcement: Exelixis (EXEL) is set to announce its Q4 earnings on February 10th after market close, with consensus EPS estimated at $0.81, reflecting a significant 47.3% year-over-year growth, indicating the company's robust performance in the oncology sector.
- Revenue Expectations: The revenue estimate for Q4 stands at $601.1 million, representing a 6.1% year-over-year increase; however, the revenue forecast has faced eight downward revisions in the last three months, suggesting some market volatility.
- Performance Track Record: Over the past two years, Exelixis has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong operational capabilities and potentially attracting more investor interest ahead of the earnings report.
- Analyst Rating Changes: Despite BofA downgrading Exelixis to Underperform due to valuation concerns and a lack of catalysts, the anticipation surrounding a potential FDA approval could still drive the stock price higher, reflecting a nuanced market perspective on the company's future prospects.
Exelixis' NDA for Zanzalintinib Accepted by FDA for Review
- FDA Review Progress: Exelixis announced that its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer has been accepted for review by the FDA, with a target action date of December 3, 2026, marking a significant advancement in cancer treatment.
- Clinical Trial Results: The phase 3 STELLAR-303 trial demonstrated that the combination of zanzalintinib and atezolizumab significantly improved median overall survival and reduced the risk of death, highlighting its potential in treating metastatic colorectal cancer.
- Market Demand Response: The introduction of zanzalintinib addresses the urgent need for effective therapies for previously treated metastatic colorectal cancer patients, potentially enhancing Exelixis' competitive position in the oncology market.
- Future Outlook: Exelixis plans to collaborate closely with the FDA to expedite the review process for zanzalintinib, which, if approved, could provide new hope for patients with metastatic colorectal cancer and further solidify the company's leadership in innovative drug development.
